Top

Supportive Care in Cancer

Published in:

01-01-2020 | Care | Original Article

Assessing quality of life in palliative care settings: head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7)

Authors: Madeleine T. King, Meera Agar, David C. Currow, Janet Hardy, Belinda Fazekas, Nikki McCaffrey

Published in: Supportive Care in Cancer | Issue 1/2020

Abstract

Purpose

Head-to-head comparison of reliability, validity and responsiveness of four patient-reported outcome measures (PROMS) suitable for assessing health-related quality of life (HRQOL) in palliative care settings: EORTC QLQ-C15-PAL, FACT-G7, FACIT-Pal and short-form FACIT-Pal-14.

Methods

Secondary analysis of two phase III randomised trials: ketamine for chronic cancer pain, octreotide for vomiting in inoperable malignant bowel obstruction. Sub-groups were defined by Australia-modified Karnofsky performance status (AKPS) and participants’ global impression of change (GIC). Two aspects of reliability were assessed: internal consistency (Cronbach alpha, α); test–retest reliability (intra-class correlation coefficient (ICC)) of patients with stable AKPS and those who self-reported ‘no change’ on GIC. Construct validity was assessed via pre-determined hypotheses about sensitivity of PROM scores to AKPS groups and responsiveness of PROM change scores to GIC groups using analysis of variance.

Results

FACIT-Pal had better internal consistency (α ranged 0.59–0.80, 15/18 ≥ 0.70) than QLQ-C15-PAL (0.51–0.85, 4/8 ≥ 0.70) and FACT-G7 (0.54–0.64, 0/2 ≥ 0.70). FACIT scales had better test–retest reliability (FACIT-Pal 11/27 ICCs ≥ 0.70, FACT-G7 2/3 ICCs ≥ 0.70) than QLQ-C15-PAL (2/30 ICCs ≥ 0.70, 18/30 ≤ 0.5). Four scales demonstrated sensitivity to AKPS: QLQ-PAL-15 Physical Functioning and Global QOL, FACT-G Functional Wellbeing and FACIT-Pal Trial Outcome Index (TOI). Nine scales demonstrated responsiveness: three in the ketamine trial population (QLQ-C15-PAL Pain, FACIT-Pal-14, FACT-G7), six in the octreotide trial population (QLQ-C15-PAL Fatigue; FACIT-Pal PalCare, TOI, Total; FACT-G Physical Wellbeing and Total).

Conclusions

No PROM was clearly superior, confirming that choosing the best PROM requires careful consideration of the research goals, patient population and the domains of HRQOL targeted by the intervention being investigated.

Available only for authorised users

World Health Organization (2015) Definition of palliative care. http://www.who.int/cancer/palliative/definition/en/. Accessed July 14 2015

FDA (2009) Food and Drug Administration. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 74(235):65132–65133

Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF, Schwartz C, Revicki DA, Moinpour CM, McLeod LD, Lyons JC, Lenderking WR, Hinds PS, Hays RD, Greenhalgh J, Gershon R, Feeny D, Fayers PM, Cella D, Brundage M, Ahmed S, Aaronson NK, Butt Z (2013) ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res 22(8):1889–1905. https://doi.org/10.1007/s11136-012-0344-y CrossRefPubMed

Aaronson N, Alonso J, Burnam A, Lohr KN, Patrick DL, Perrin E, Stein RE (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 11(3):193–205CrossRef

Osoba D (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol : Off J Am Soc Clin Oncol 12(3):608–616. https://doi.org/10.1200/jco.1994.12.3.608 CrossRef

Albers G, Echteld MA, de Vet HC, Onwuteaka-Philipsen BD, van der Linden MH, Deliens L (2010) Content and spiritual items of quality-of-life instruments appropriate for use in palliative care: a review. J Pain Symptom Manag 40(2):290–300. https://doi.org/10.1016/j.jpainsymman.2009.12.012 CrossRef

Albers G, Echteld MA, de Vet HC, Onwuteaka-Philipsen BD, van der Linden MH, Deliens L (2010) Evaluation of quality-of-life measures for use in palliative care: a systematic review. Palliat Med 24(1):17–37. https://doi.org/10.1177/0269216309346593 CrossRefPubMed

Shahidi J, Bernier N, Cohen SR (2010) Quality of life in terminally ill cancer patients: contributors and content validity of instruments. J Palliat Care 26(2):88–93CrossRef

McCaffrey N, Bradley S, Ratcliffe J, Currow DC (2016) What aspects of quality of life are important from palliative care patients’ perspectives? A systematic review of qualitative research. J Pain Symptom Manag 52(2):318–328.e315. https://doi.org/10.1016/j.jpainsymman.2016.02.012 CrossRef

10.

Jones JM, McPherson CJ, Zimmermann C, Rodin G, Le LW, Cohen SR (2011) Assessing agreement between terminally ill cancer patients’ reports of their quality of life and family caregiver and palliative care physician proxy ratings. J Pain Symptom Manag 42(3):354–365. https://doi.org/10.1016/j.jpainsymman.2010.11.018 CrossRef

11.

Petersen MA, Larsen H, Pedersen L, Sonne N, Groenvold M (2006) Assessing health-related quality of life in palliative care: comparing patient and physician assessments. Eur J Cancer 42(8):1159–1166CrossRef

12.

Lyons KD, Bakitas M, Hegel MT, Hanscom B, Hull J, Ahles TA (2009) Reliability and validity of the Functional Assessment of Chronic Illness Therapy-Palliative care (FACIT-Pal) scale. J Pain Symptom Manag 37(1):23–32. https://doi.org/10.1016/j.jpainsymman.2007.12.015 CrossRef

13.

Zeng L, Bedard G, Cella D, Thavarajah N, Chen E, Zhang L, Bennett M, Peckham K, De Costa S, Beaumont JL, Tsao M, Danjoux C, Barnes E, Sahgal A, Chow E (2013) Preliminary results of the generation of a shortened quality-of-life assessment for patients with advanced cancer: the FACIT-Pal-14. J Palliat Med 16(5):509–515. https://doi.org/10.1089/jpm.2012.0595 CrossRefPubMed

14.

Chiu L, Chiu N, Chow E, Cella D, Beaumont JL, Lam H, Popovic M, Bedard G, Poon M, Wong E, Zeng L, Bottomley A (2014) Comparison of three shortened questionnaires for assessment of quality of life in advanced cancer. J Palliat Med 17(8):918–923. https://doi.org/10.1089/jpm.2014.0012 CrossRefPubMed

15.

Yanez B, Pearman T, Lis CG, Beaumont JL, Cella D (2013) The FACT-G7: a rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research. Ann Oncol : Off J Eur Soc Med Oncol 24(4):1073–1078. https://doi.org/10.1093/annonc/mds539 CrossRef

16.

Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Bjorner JB, Group EQoL (2006) The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 42(1):55–64CrossRef

17.

Lien K, Zeng L, Nguyen J, Cramarossa G, Culleton S, Caissie A, Lutz S, Chow E (2011) Comparison of the EORTC QLQ-C15-PAL and the FACIT-Pal for assessment of quality of life in patients with advanced cancer. Expert Rev Dermatol 11(5):541–547. https://doi.org/10.1586/erp.11.64 CrossRef

18.

Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, Eckermann S, Abernethy AP, Clark K (2015) Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manag 49(5):814–821. https://doi.org/10.1016/j.jpainsymman.2014.09.013 CrossRef

19.

Hardy J, Quinn S, Fazekas B, Plummer J, Eckermann S, Agar M, Spruyt O, Rowett D, Currow DC (2012) Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol : Off J Am Soc Clin Oncol 30(29):3611–3617. https://doi.org/10.1200/jco.2012.42.1081 CrossRef

20.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRef

21.

Groenvold M, Petersen MA, EORTC_Quality_of_Life_Group obot (2006) Addendum to the EORTC QLQ-C30 Scoring Manual: Scoring of the EORTC QLQ-C15-PAL

22.

Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579. https://doi.org/10.1200/JCO.1993.11.3.570 CrossRefPubMed

23.

Fairclough DL, Cella DF (1996) Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Qual Life Res 5(3):321–329CrossRef

24.

Revicki D, Hays RD, Cella D, Sloan J (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102–109. https://doi.org/10.1016/j.jclinepi.2007.03.012 CrossRefPubMed

25.

Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC (2005) The Australia-modified Karnofsky performance status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481]. BMC palliative care 4:7. https://doi.org/10.1186/1472-684x-4-7 CrossRefPubMedPubMedCentral

26.

Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60(1):34–42CrossRef

27.

Streiner DL, Norman GR, Cairney J (2015) Health measurement scales—a practical guide to their development and use, 5th edn. Oxford University Press, Oxford, UK

28.

Fayers PM, Machin D (2016) Quality of life: the assessment, analysis and reporting of patient-reported outcomes. John Wiley & Sons, Ltd., West Sussex, UK

29.

Cohen J (1992) A power primer. Psychol Bull 112(1):155–159CrossRef

30.

Alawneh A, Yasin H, Khirfan G, Qayas BA, Ammar K, Rimawi D, Klepstad P (2016) Psychometric properties of the Arabic version of EORTC QLQ-C15-PAL among cancer patients in Jordan. Support Care Cancer 24(6):2455–2462. https://doi.org/10.1007/s00520-015-3018-9 CrossRefPubMed

31.

Ozcelik H, Guzel Y, Sonmez E, Aksoy F, Uslu R (2016) Reliability and validity of the Turkish version of the EORTC QLQ-C15-PAL for patients with advanced cancer. Palliat Support Care 14(6):628–634CrossRef

32.

Arraras JI, de la Vega FA, Asin G, Rico M, Zarandona U, Eito C, Cambra K, Barrondo M, Errasti M, Verdun J, Rivadeneira J, Dominguez MA (2014) The EORTC QLQ-C15-PAL questionnaire: validation study for Spanish bone metastases patients. Qual Life Res 23(3):849–855. https://doi.org/10.1007/s11136-013-0511-9 CrossRefPubMed

33.

Miyashita M, Wada M, Morita T, Ishida M, Onishi H, Sasaki Y, Narabayashi M, Wada T, Matsubara M, Takigawa C, Shinjo T, Suga A, Inoue S, Ikenaga M, Kohara H, Tsuneto S, Shima Y (2015) Independent validation of the Japanese version of the EORTC QLQ-C15-PAL for patients with advanced cancer. J Pain Symptom Manag 49(5):953–959. https://doi.org/10.1016/j.jpainsymman.2014.11.299 CrossRef

34.

Miyazaki K, Suzukamo Y, Shimozuma K, Nakayama T (2012) Verification of the psychometric properties of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 palliative (EORTCQLQ-C15-PAL). Qual Life Res 21(2):335–340. https://doi.org/10.1007/s11136-011-9939-y CrossRefPubMed

35.

Nunes NA (2014) The quality of life of Brazilian patients in palliative care: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 PAL (EORTC QLQ-C15-PAL). Support Care Cancer 22(6):1595–1600. https://doi.org/10.1007/s00520-014-2119-1 CrossRefPubMed

36.

Shin DW, Choi JE, Miyashita M, Choi JY, Kang J, Baik YJ, Mo HN, Park J, Kim HJ, Park EC (2011) Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 15-Palliative Care. J Pain Symptom Manag 41(2):478–484. https://doi.org/10.1016/j.jpainsymman.2010.05.009 CrossRef

37.

Suarez-del-Real Y, Allende-Perez S, Alferez-Mancera A, Rodriguez RB, Jimenez-Toxtle S, Mohar A, Onate-Ocana LF (2011) Validation of the Mexican-Spanish version of the EORTC QLQ-C15-PAL questionnaire for the evaluation of health-related quality of life in patients on palliative care. Psychooncology 20(8):889–896. https://doi.org/10.1002/pon.1801 CrossRefPubMed

38.

Zhang L, Wang N, Zhang J, Liu J, Luo Z, Sun W, Woo SM, Chen C, Zhang K, Miller AR, Guo H, Zhang X, Wang C (2016) Cross-cultural verification of the EORTC QLQ-C15-PAL questionnaire in mainland China. Palliat Med 30(4):401–408. https://doi.org/10.1177/0269216315593671 CrossRefPubMed

39.

Siegert R, Selman L, Higginson IJ, Ali Z, Powell RA, Namisango E, Mwangi-Powell F, Gwyther L, Gikaara N, Harding R (2014) A psychometric evaluation of the functional assessment of chronic illness therapy-palliative care (FACIT-pal) scale with palliative care samples in three African countries. J Pain Symptom Manag 48(5):983–991. https://doi.org/10.1016/j.jpainsymman.2014.01.010 CrossRef

40.

Caissie A, Nguyen J, Chen E, Zhang L, Sahgal A, Clemons M, Kerba M, Arnalot PF, Danjoux C, Tsao M, Barnes E, Holden L, Danielson B, Chow E (2012) Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL. Int J Radiat Oncol Biol Phys 83(4):1238–1245. https://doi.org/10.1016/j.ijrobp.2011.09.025 CrossRefPubMed

41.

Caissie A, Zeng L, Nguyen J, Zhang L, Jon F, Dennis K, Holden L, Culleton S, Koo K, Tsao M, Barnes E, Danjoux C, Sahgal A, Simmons C, Chow E (2012) Assessment of health-related quality of life with the European Organization for Research and Treatment of Cancer QLQ-C15-PAL after palliative radiotherapy of bone metastases. Clin Oncol (R Coll Radiol) 24(2):125–133. https://doi.org/10.1016/j.clon.2011.08.008 CrossRef

42.

Lee YJ, Suh SY, Choi YS, Shim JY, Seo AR, Choi SE, Ahn HY, Yim E (2014) EORTC QLQ-C15-PAL quality of life score as a prognostic indicator of survival in patients with far advanced cancer. Support Care Cancer 22(7):1941–1948. https://doi.org/10.1007/s00520-014-2173-8 CrossRefPubMed

43.

Mercieca-Bebber R, Palmer MJ, Brundage M, Calvert M, Stockler MR, King MT (2016) Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review. BMJ Open 6(6):e010938. https://doi.org/10.1136/bmjopen-2015-010938 CrossRefPubMedPubMedCentral

44.

Luckett T, King MT (2010) Choosing patient-reported outcome measures for cancer clinical research--practical principles and an algorithm to assist non-specialist researchers. Eur J Cancer 46(18):3149–3157. https://doi.org/10.1016/j.ejca.2010.08.002 CrossRefPubMed

45.

Snyder CF, Watson ME, Jackson JD, Cella D, Halyard MY, Mayo FDAP-ROCMG (2007) Patient-reported outcome instrument selection: designing a measurement strategy. Value Health 10(Suppl 2):S76–S85. https://doi.org/10.1111/j.1524-4733.2007.00270.x CrossRefPubMed

Title: Assessing quality of life in palliative care settings: head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7)
Authors: Madeleine T. King
Meera Agar
David C. Currow
Janet Hardy
Belinda Fazekas
Nikki McCaffrey
Publication date: 01-01-2020
Publisher: Springer Berlin Heidelberg
Keywords: Care
Ketamine
Published in: Supportive Care in Cancer / Issue 1/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-04754-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

The use of stretching devices for treatment of trismus in head and neck cancer patients: a randomized controlled trial

MASCC recommendations on the management of constipation in patients with advanced cancer

Predictors of chemotherapy-induced severe anemia in cancer patients receiving chemotherapy

Health-related and cancer-related Internet use by patients treated with total laryngectomy

Oral health–related quality of life in breast cancer survivors

A cross-sectional audit of current practices and areas for improvement of distress screening and management in Australian cancer services: is there a will and a way to improve?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer